PT761213E - Metodo para a producao de uma preparacao de libertacao controlada - Google Patents

Metodo para a producao de uma preparacao de libertacao controlada

Info

Publication number
PT761213E
PT761213E PT96306191T PT96306191T PT761213E PT 761213 E PT761213 E PT 761213E PT 96306191 T PT96306191 T PT 96306191T PT 96306191 T PT96306191 T PT 96306191T PT 761213 E PT761213 E PT 761213E
Authority
PT
Portugal
Prior art keywords
microcapsules
release
biodegradable polymer
bioactive substance
production
Prior art date
Application number
PT96306191T
Other languages
English (en)
Inventor
Yasutaka Igari
Shigeyuki Takada
Hiroshi Kosakai
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of PT761213E publication Critical patent/PT761213E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PT96306191T 1995-09-04 1996-08-27 Metodo para a producao de uma preparacao de libertacao controlada PT761213E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22645795 1995-09-04

Publications (1)

Publication Number Publication Date
PT761213E true PT761213E (pt) 2003-02-28

Family

ID=16845403

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96306191T PT761213E (pt) 1995-09-04 1996-08-27 Metodo para a producao de uma preparacao de libertacao controlada

Country Status (13)

Country Link
US (1) US6045830A (pt)
EP (1) EP0761213B1 (pt)
KR (1) KR100409413B1 (pt)
CN (1) CN1080559C (pt)
AT (1) ATE226431T1 (pt)
CA (1) CA2184654A1 (pt)
DE (1) DE69624426T2 (pt)
DK (1) DK0761213T3 (pt)
ES (1) ES2180706T3 (pt)
HU (1) HUP9602426A3 (pt)
NO (1) NO963678L (pt)
PT (1) PT761213E (pt)
TW (1) TW448055B (pt)

Families Citing this family (286)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100354270B1 (ko) * 1993-11-19 2003-02-11 알커메스 컨트롤드 테라포이틱스 인코퍼레이티드 Ii 마이크로캡슐화된3-피페리디닐-치환된1,2-벤즈이속사졸및1,2-벤즈이소티아졸
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
US6190702B1 (en) * 1996-03-28 2001-02-20 Takeda Chemical Industries, Ltd. Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase
DE69906254T2 (de) 1998-01-21 2003-11-13 Takeda Chemical Industries Ltd Verfahren zur gerfriertrocknung von präparaten mit verzörgerter wirkstoffabgabe
US7282219B2 (en) * 2000-03-31 2007-10-16 Kirin Beer Kabushiki Kaisha Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
CA2430934C (en) 2000-12-01 2011-06-21 Takeda Chemical Industries, Ltd. A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
WO2002087616A1 (fr) * 2001-04-25 2002-11-07 Takeda Chemical Industries, Ltd. Remedes contre la recurrence postoperative du cancer du sein chez les femmes en premenopause
JP2004535431A (ja) 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド ゼロ次長期放出同軸インプラント
US7300915B2 (en) 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
ES2605402T3 (es) 2002-06-25 2017-03-14 Takeda Pharmaceutical Company Limited Procedimiento para producir una composición de liberación sostenida
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
CA2575988C (en) * 2004-08-04 2014-02-18 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
WO2006130217A2 (en) * 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates
US8222257B2 (en) 2005-04-01 2012-07-17 The Regents Of The University Of California Phosphono-pent-2-en-1-yl nucleosides and analogs
US20100204243A1 (en) * 2005-04-11 2010-08-12 Lifecare Innovations Pvt. Ltd. Process for the Preparation of Poly DL-Lactide-Co-Glycolide Nanoparticles Having Antitubercular Drugs Encapsulated Therein
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
US20070190127A1 (en) 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
JP2009530284A (ja) * 2006-03-13 2009-08-27 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド 拡張期心不全を治療するための方法と組成物
MX2008011844A (es) * 2006-03-13 2008-10-02 Encysive Pharmaceuticals Inc Formulaciones de sitaxsentano de sodio.
CN101443314B (zh) * 2006-03-13 2014-04-09 杏林制药株式会社 作为gsk-3抑制剂的氨基喹诺酮类
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
US7879846B2 (en) 2006-09-21 2011-02-01 Kyorin Pharmaceutical Co.., Ltd. Serine hydrolase inhibitors
DE602007013440D1 (de) 2006-10-19 2011-05-05 Auspex Pharmaceuticals Inc Substituierte indole
JP5196760B2 (ja) * 2006-10-27 2013-05-15 一般財団法人 九州医療資源財団 Ｗ／ｏ／ｗ型エマルジョン組成物
US20100137421A1 (en) * 2006-11-08 2010-06-03 Emmanuel Theodorakis Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
KR100816065B1 (ko) 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
BRPI0720582B1 (pt) 2006-12-18 2021-08-24 Takeda Pharmaceutical Company Limited Composição de liberação prolongada, processo para a preparação da mesma, composição farmacêutica, agente profilático ou terapêutico, e, uso de uma substância fisiologicamente ativa
WO2008079371A1 (en) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
AU2008219622A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
EP3103790B1 (en) 2007-03-15 2018-05-09 Auspex Pharmaceuticals, Inc. Substituted phenethylamine with serotoninergic and/or norepinephrinergic activity
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
US8247423B2 (en) * 2007-07-12 2012-08-21 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
AU2008299903B2 (en) * 2007-09-11 2013-08-29 Kyorin Pharmaceutical Co., Ltd Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
KR101597841B1 (ko) 2007-09-12 2016-02-26 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-３ 억제제로서의 스피로시클릭 아미노퀴놀론
ES2718612T3 (es) 2007-12-20 2019-07-03 Evonik Corp Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
PL2268623T3 (pl) * 2008-03-17 2015-10-30 Ambit Biosciences Corp Pochodne chinazoliny jako modulatory kinazy RAF oraz sposoby ich zastosowania
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
EP2303327A2 (en) * 2008-05-20 2011-04-06 Cerenis Therapeutics S.A. Niacin and nsaid for combination therapy
KR20110065440A (ko) 2008-07-02 2011-06-15 아이데닉스 파마슈티칼스, 인코포레이티드 바이러스 감염의 치료를 위한 화합물 및 제약 조성물
US20100015240A1 (en) * 2008-07-16 2010-01-21 Danielle Biggs Process for preparing microparticles containing bioactive peptides
KR101113044B1 (ko) 2008-08-29 2012-02-27 동국제약 주식회사 용매교류증발법에 의한 서방출성 미립구의 제조방법
EP2376524B1 (en) 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
CN102395576A (zh) * 2009-02-27 2012-03-28 埃姆比特生物科学公司 调控jak激酶的喹唑啉衍生物和其使用方法
EP2403860B1 (en) 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
MX2011009414A (es) * 2009-03-11 2011-10-19 Kyorin Seiyaku Kk 7-cicloalquiloaminoquinolonas como inhibidores de gsk-3.
MX2011009413A (es) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
AU2010229468A1 (en) 2009-03-27 2011-10-13 Vetdc, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
EP2502921B1 (en) 2009-04-22 2015-05-20 Axikin Pharmaceuticals, Inc. Arylsulfonamide CCR3 antagonists
DK2421829T3 (en) 2009-04-22 2016-01-04 Axikin Pharmaceuticals Inc 2,5-disubstituted aryl sulfonamide CCR3 antagonists
KR101687144B1 (ko) 2009-04-22 2016-12-15 액시킨 파마수티컬스 인코포레이티드 2,5-이치환된 아릴설폰아마이드 ｃｃｒ3 길항제
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
CA2987503C (en) 2009-07-07 2019-02-26 Mei Pharma, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
AU2010270605B2 (en) 2009-07-08 2014-07-31 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
WO2011009961A1 (en) 2009-07-24 2011-01-27 Virologik Gmbh Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
EP2467137A1 (en) 2009-08-19 2012-06-27 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
WO2011056566A2 (en) 2009-10-26 2011-05-12 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
CN102822175A (zh) 2009-12-18 2012-12-12 埃迪尼克斯医药公司 5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂
SG181896A1 (en) * 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
CA2785978A1 (en) 2009-12-30 2011-07-07 Scynexis, Inc. Cyclosporine analogues
WO2011089166A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
EP2531197B1 (en) 2010-02-05 2017-05-17 Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
PT3202460T (pt) 2010-02-11 2019-08-05 Celgene Corp Derivados arilmetoxi-indolina e composições que os compreendem e métodos para a sua utilização
ES2542404T3 (es) 2010-03-02 2015-08-05 Axikin Pharmaceuticals, Inc. Antagonistas de CCR3 de tipo arilsulfonamida enriquecidos isotópicamente
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
JP5818873B2 (ja) 2010-03-17 2015-11-18 アクシキン ファーマシューティカルズ インコーポレーテッド アリールスルホンアミドｃｃｒ３アンタゴニスト
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
CA2801001A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
AU2011261501B2 (en) 2010-06-01 2016-01-21 Biotheryx, Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
CN103108868B (zh) 2010-06-07 2015-11-25 诺沃梅迪科斯有限公司 呋喃基化合物及其用途
US20130178522A1 (en) 2010-07-19 2013-07-11 James M. Jamison Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
EP2611809A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
WO2012030913A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
EP2663553B1 (en) 2010-09-01 2015-08-26 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
US20130225578A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
EP2611502A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
WO2012030910A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
WO2012030914A1 (en) 2010-09-01 2012-03-08 Ambit Boisciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
EP2611812A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
WO2012030948A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
CA2809983A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
CN103298786B (zh) 2010-10-11 2016-01-20 埃克希金医药品有限公司 芳基磺酰胺盐ccr3拮抗剂
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2014500275A (ja) 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
UA115767C2 (uk) 2011-01-10 2017-12-26 Інфініті Фармасьютікалз, Інк. Способи отримання ізохінолінонів і тверді форми ізохінолінонів
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
BR112013023277A2 (pt) 2011-03-11 2017-06-27 Celgene Corp métodos de tratamento de câncer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidibna-2,6-diona
CA2831582C (en) 2011-03-28 2019-01-08 Mei Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
EP2691388A1 (en) 2011-03-28 2014-02-05 MEI Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
EP2691389A1 (en) 2011-03-28 2014-02-05 MEI Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
JP5825183B2 (ja) 2011-04-25 2015-12-02 コニカミノルタ株式会社 静電荷像現像用トナーの製造方法
US8604035B2 (en) 2011-06-23 2013-12-10 Map Pharmaceuticals, Inc. Fluoroergoline analogs
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2013039855A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013039920A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
MY167575A (en) 2011-10-14 2018-09-20 Ambit Biosciences Corp Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
SG11201403434YA (en) 2011-12-19 2014-09-26 Map Pharmaceuticals Inc Novel iso-ergoline derivatives
EP2793583A4 (en) 2011-12-21 2015-08-12 Map Pharmaceuticals Inc NOVEL NEUROMODULATORY CONNECTIONS
US9611253B2 (en) 2012-02-29 2017-04-04 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
CA2867467A1 (en) 2012-03-16 2013-09-19 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
AU2013266393B2 (en) 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
JP6250671B2 (ja) 2012-08-09 2017-12-20 セルジーン コーポレイション 免疫関連及び炎症性疾患の治療
IN2015DN00885A (pt) 2012-08-09 2015-06-12 Celgene Corp
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
CN104781240A (zh) 2012-09-07 2015-07-15 埃克希金医药品有限公司 同位素富集的芳基磺酰胺ccr3拮抗剂
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
GEP201706723B (en) 2012-10-08 2017-08-25 Idenix Pharmaceuticals Llk 2'-chloro nucleoside analogs for hcv infection
WO2014063019A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
HUE040126T2 (hu) 2012-11-01 2019-02-28 Infinity Pharmaceuticals Inc Rákok kezelése PI3 kináz izoform modulátorok alkalmazásával
CA2890177A1 (en) 2012-11-08 2014-05-15 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
EP2925718B1 (en) 2012-11-30 2018-08-01 Novomedix, LLC Substituted biaryl sulfonamides and the use thereof
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
WO2014100354A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Novel methysergide derivatives
CA2897665A1 (en) 2013-01-11 2014-07-17 Mayo Foundation For Medical Education And Research Vitamins c and k for treating polycystic diseases
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
BR112015029969A2 (pt) 2013-05-30 2017-07-25 Infinity Pharmaceuticals Inc tratamento de câncer usando moduladores de isoformas quinase pi3
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EP3039021A1 (en) 2013-08-30 2016-07-06 Ambit Biosciences Corporation Biaryl acetamide compounds and methods of use thereof
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015051336A1 (en) 2013-10-03 2015-04-09 David Wise Compositions and methods for treating pelvic pain and other conditions
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA201690713A1 (ru) 2013-10-04 2016-08-31 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015066370A1 (en) 2013-11-01 2015-05-07 Idenix Pharmaceuticals, Inc. D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
EP3074411A2 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC Nucleotides for the treatment of liver cancer
WO2015081297A1 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
US10683321B2 (en) 2013-12-18 2020-06-16 Idenix Pharmaceuticals Llc 4′-or nucleosides for the treatment of HCV
EP3114122A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid forms of a flaviviridae virus inhibitor compound and salts thereof
DK3119397T3 (da) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
AU2015231215B2 (en) 2014-03-20 2019-07-18 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
PT3119762T (pt) 2014-03-20 2021-08-31 Capella Therapeutics Inc Derivados de benzimidazole como inibidores de tirosina quinase erbb para o tratamento do cancro
AU2015243437B2 (en) 2014-04-09 2019-08-29 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins useful for the treatment of pain
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
BR112016026560A2 (pt) 2014-05-12 2017-08-15 Conatus Pharmaceuticals Inc Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção
WO2015181624A2 (en) 2014-05-28 2015-12-03 Idenix Pharmaceuticals, Inc Nucleoside derivatives for the treatment of cancer
WO2015195474A1 (en) 2014-06-18 2015-12-23 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
EA034691B1 (ru) 2014-06-19 2020-03-06 Ариад Фармасьютикалз, Инк. Гетероарильные соединения для ингибирования киназ
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2016040860A1 (en) 2014-09-12 2016-03-17 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10385078B2 (en) 2014-10-21 2019-08-20 Ariad Pharmaceuticals, Inc. Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
EP3209658A1 (en) 2014-10-24 2017-08-30 Biogen MA Inc. Diterpenoid derivatives and methods of use thereof
SG11201705088VA (en) 2014-12-23 2017-07-28 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
EP3253753A4 (en) 2015-01-20 2018-06-27 Xoc Pharmaceuticals, Inc Ergoline compounds and uses thereof
US9676776B2 (en) 2015-01-20 2017-06-13 Xoc Pharmaceuticals, Inc. Isoergoline compounds and uses thereof
EP3303361A1 (en) 2015-05-27 2018-04-11 Idenix Pharmaceuticals LLC Nucleotides for the treatment of cancer
MX2017017015A (es) 2015-06-23 2018-02-26 Neurocrine Biosciences Inc Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos.
PT3385395T (pt) 2015-08-17 2020-05-06 Kura Oncology Inc Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
KR101779846B1 (ko) 2015-08-31 2017-10-10 주식회사 티케이케미칼 나노다공성을 갖는 서방성 미분말과 그 제조방법
CN108473503A (zh) 2015-09-30 2018-08-31 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
MA43116B1 (fr) 2015-10-30 2021-04-30 Neurocrine Biosciences Inc Ditosylate de valbénazine et polymorphes associés
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
JP6869988B2 (ja) 2015-12-23 2021-05-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド （Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
RU2018127752A (ru) 2015-12-31 2020-01-31 Конатус Фармасьютикалз Инк. Способы применения ингибиторов каспаз при лечении заболеваний печени
PL3399978T3 (pl) 2016-01-08 2021-04-06 Celgene Corporation Związki antyproliferacyjne oraz ich kompozycje farmaceutyczne i zastosowania
EP3399980A4 (en) 2016-01-08 2019-09-04 Celgene Corporation METHODS OF TREATING CANCER AND USE OF BIOMARKERS AS FACTORS PREDICTIVE OF CLINICAL SENSITIVITY TO TREATMENTS
JP7071922B2 (ja) 2016-01-08 2022-05-19 セルジーン コーポレイション ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの固体形態、ならびにそれらの薬学的組成物及び使用
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
EP3442940A1 (en) 2016-04-11 2019-02-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
US11497738B2 (en) 2016-04-29 2022-11-15 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3036195A1 (en) 2016-09-07 2018-03-15 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
WO2018053437A1 (en) 2016-09-19 2018-03-22 Mei Pharma, Inc. Combination therapy
MX2019005065A (es) 2016-11-03 2019-08-21 Kura Oncology Inc Metodos de tratamiento de pacientes con cancer con inhibidores de farnesiltransferasa.
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
CN116987014A (zh) 2016-11-09 2023-11-03 诺沃梅迪科斯有限公司 1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
EP3548007A4 (en) 2016-12-01 2020-08-12 Ignyta, Inc. CANCER TREATMENT METHODS
EP3548027A1 (en) 2016-12-02 2019-10-09 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
KR20200066662A (ko) 2017-01-27 2020-06-10 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
US9956215B1 (en) 2017-02-21 2018-05-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
SG11201907594TA (en) 2017-02-21 2019-09-27 Kura Oncology Inc Methods of treating cancer with farnesyltransferase inhibitors
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
US11555031B2 (en) 2017-03-20 2023-01-17 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
US11279706B2 (en) 2017-03-29 2022-03-22 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
CA3058214A1 (en) 2017-03-29 2018-10-04 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
MX2019013561A (es) 2017-05-19 2022-02-09 Nflection Therapeutics Inc Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
WO2018213807A1 (en) 2017-05-19 2018-11-22 Nflection Therapeutics, Inc. Fused heteroaromatic-aniline compounds for treatment of dermal disorders
AU2018275873A1 (en) 2017-06-01 2019-12-19 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
KR20200051601A (ko) 2017-08-07 2020-05-13 쿠라 온콜로지, 인크. 파르네실전달효소 억제제를 이용하여 암을 치료하는 방법
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MX2020002841A (es) 2017-09-21 2020-07-22 Neurocrine Biosciences Inc Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma.
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
EA202090932A1 (ru) 2017-10-10 2021-05-20 Нейрокрин Байосайенсиз, Инк Способы введения некоторых vmat2-ингибиторов
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
US20210052529A1 (en) 2018-01-10 2021-02-25 Cura Therapeutics, Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
CA3087856A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
MA52896A (fr) 2018-06-14 2021-04-21 Neurocrine Biosciences Inc Composés inhibiteurs de vmat2, compositions et méthodes associées
US11447497B2 (en) 2018-06-29 2022-09-20 Histogen, Inc. (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
CA3104693A1 (en) 2018-08-15 2020-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
US20220009938A1 (en) 2018-10-03 2022-01-13 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
CN113286591A (zh) 2018-11-01 2021-08-20 库拉肿瘤学公司 用法尼基转移酶抑制剂治疗癌症的方法
WO2020106307A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
US20220144819A1 (en) 2018-11-20 2022-05-12 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
JP2022513089A (ja) 2018-11-20 2022-02-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚癌の処置のためのアリールアニリンおよびヘテロアリールアニリン化合物
CN113473978A (zh) 2018-11-20 2021-10-01 恩福莱克逊治疗有限公司 用于治疗皮肤疾病氰基芳烃-苯胺化合物
WO2020132071A1 (en) 2018-12-19 2020-06-25 Shy Therapeutics. Llc Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
US20220071941A1 (en) 2018-12-21 2022-03-10 Kura Oncology, Inc. Therapies for squamous cell carcinomas
CN109700780B (zh) * 2019-01-31 2021-02-12 浙江圣兆药物科技股份有限公司 一种高包封率的亲水性药物缓释微球及其制备方法
EP3921038A1 (en) 2019-02-06 2021-12-15 Dice Alpha, Inc. Il-17a modulators and uses thereof
WO2020180663A1 (en) 2019-03-01 2020-09-10 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
AU2020231396A1 (en) 2019-03-07 2021-10-21 Nobo Medicine Inc. Caspase inhibitors and methods of use thereof
WO2020190604A1 (en) 2019-03-15 2020-09-24 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2020205486A1 (en) 2019-03-29 2020-10-08 Kura Oncology, Inc. Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220177815A1 (en) * 2019-04-12 2022-06-09 International Flavors & Fragrances Inc. Controlled release, biodegradable core-shell microcapsule compositions
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
CA3146157A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
CA3146159A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
CN114126593A (zh) 2019-07-26 2022-03-01 埃斯佩尔维塔治疗股份有限公司 可用于预防或治疗疾病的官能化的长链烃一元和二元羧酸
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
JP2022547617A (ja) 2019-09-16 2022-11-14 ダイス アルファ，インク． Ｉｌ－１７ａモジュレーターおよびその使用
US20230008367A1 (en) 2019-09-26 2023-01-12 Abionyx Pharma Sa Compounds useful for treating liver diseases
KR20220091488A (ko) 2019-10-01 2022-06-30 몰레큘러 스킨 테라퓨틱스, 인코포레이티드 Klk5/7 이중 억제제로서의 벤족사지논 화합물
WO2021242970A1 (en) 2020-05-29 2021-12-02 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
EP4168414A1 (en) 2020-06-18 2023-04-26 Shy Therapeutics LLC Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
IL300626A (en) 2020-08-14 2023-04-01 Siteone Therapeutics Inc Ketone-free inhibitors of NAV1.7 for the treatment of pain
US20240124483A1 (en) 2021-01-27 2024-04-18 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
IL305752A (en) 2021-03-10 2023-11-01 Dice Molecules Sv Inc INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES
EP4326721A1 (en) 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4347568A1 (en) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
TW202327590A (zh) 2021-11-30 2023-07-16 美商庫拉腫瘤技術股份有限公司 大環化合物及組合物以及其製備及使用方法
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
US11981694B2 (en) 2022-01-03 2024-05-14 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
TW202400593A (zh) 2022-03-28 2024-01-01 美商艾索司特瑞克斯公司 Ｍｙｓｔ家族離胺酸乙醯轉移酶之抑制劑
TW202342070A (zh) 2022-03-30 2023-11-01 美商拜奧馬林製藥公司 肌萎縮蛋白外顯子跳躍寡核苷酸
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
TW202406901A (zh) 2022-04-14 2024-02-16 美商必治妥美雅史谷比公司 新穎gspt1化合物以及新穎化合物之使用方法
WO2023201348A1 (en) 2022-04-15 2023-10-19 Celgene Corporation Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
WO2023215781A1 (en) 2022-05-05 2023-11-09 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
WO2024054832A1 (en) 2022-09-09 2024-03-14 Innovo Therapeutics, Inc. CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
US20240131005A1 (en) 2022-09-30 2024-04-25 Boulder Bioscience Llc Compositions and methods for treating non-hemorrhagic closed head injury
WO2024086246A2 (en) 2022-10-18 2024-04-25 Eluciderm Inc. 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
US20240174673A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds
US20240174672A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridone Compounds
WO2024092040A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4612364A (en) * 1984-10-05 1986-09-16 Takeda Chemical Industries Method for producing formed product of high molecular compounds
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
CA1334379C (en) * 1987-11-24 1995-02-14 James William Mcginity Method for preparing a solid sustained release form of a functionally active composition
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
DE69129770T2 (de) * 1990-04-13 1998-11-19 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare Polymere, ihre Herstellung und ihre Verwendung
JPH04217914A (ja) * 1990-05-10 1992-08-07 Nkk Corp 徐放性製剤の製造方法
GB2246514B (en) * 1990-08-01 1993-12-15 Scras Sustained release pharmaceutical compositions and the preparation of particles for use therein
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
BR9509201A (pt) * 1994-09-09 1997-12-30 Takeda Chemical Industries Ltd Preparação de liberação sustemtada uso de um sal de metal polivalente insolúvel em água ou ligeiramente solúvel em água e processo para produzir uma preparação de liberação sustentada

Also Published As

Publication number Publication date
HUP9602426A2 (en) 1997-06-30
EP0761213A2 (en) 1997-03-12
HUP9602426A3 (en) 1998-01-28
HU9602426D0 (en) 1996-10-28
DE69624426T2 (de) 2003-03-06
CN1080559C (zh) 2002-03-13
NO963678D0 (no) 1996-09-03
DE69624426D1 (de) 2002-11-28
NO963678L (no) 1997-03-05
EP0761213A3 (en) 1998-04-01
DK0761213T3 (da) 2003-02-03
TW448055B (en) 2001-08-01
KR100409413B1 (ko) 2004-04-30
CN1148956A (zh) 1997-05-07
ATE226431T1 (de) 2002-11-15
EP0761213B1 (en) 2002-10-23
KR970014761A (ko) 1997-04-28
CA2184654A1 (en) 1997-03-05
ES2180706T3 (es) 2003-02-16
US6045830A (en) 2000-04-04

Similar Documents

Publication Publication Date Title
PT761213E (pt) Metodo para a producao de uma preparacao de libertacao controlada
DE69322917T2 (de) Verfahren zur Herstellung von Mikrokapseln mit verzögerter Wirkstoffabgabe
NO177984C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat i mikrokapselform, ved hjelp av et herdingsmiddel
DE3872382D1 (de) Pharmazeutische zusammensetzungen mit verlaengerter wirkung und verfahren zu ihrer herstellung.
DE69621317D1 (de) Herstellung einer langsam freisetzenden Zubereitung zur Injektion
PT1310517E (pt) Polimero de acido lactico e processo para a sua producao
ES2055292T3 (es) Procedimiento de microencapsulacion.
BR9204577A (pt) Processo para obtencao de uma formulacao de liberacao controlada estabilizada,produto estabilizado e forma de dosagem solida de liberacao controlada estabilizada
PT98397A (pt) Processo para a preparacao de microcapsulas para administracao de uma composicao farmaceutica com libertacao controlada duma proteina ou dum polipeptido mediante integracao com um polimero hidrofobico biodegradavel
NO180801C (no) Fremgangsmåte til fremstilling av et frysetörket preparat
DK0690747T3 (da) Fremgangsmåde til fremstilling af partikler indeholdende en aktiv bestanddel under anvendelse af ekstrudering og frysetørring
DK1058542T3 (da) Fremgangsmåde til fremstilling af indkapslede sfærisk granulatkorn
BR9204499A (pt) Processo para reticulacao de um polimero,composicao de revestimento,composto e processo para producao de uma melanina modificada com acido
KR950016697A (ko) 히알루론산 또는 그 알칼리금속염을 함유하는 마이크로캡슐을 함유하는 신규의 서방형 보습성 립스틱 및 그 제조방법
BRPI9607752B8 (pt) formulação farmacêutica de microcápsula de liberação controlada.
RU95118767A (ru) Способ приготовления сухого лактобактерина ацидофильного препарата "наринэ-лан"